|
1.
|
Ono T, Kitaura H, Ugai H, Murata T,
Yokoyama KK, Iguchi-Ariga SM and Ariga H: Tok-1, a novel
p21Cip1-binding protein that cooperatively enhances
p21-dependent inhibitory activity toward CDK2 kinase. J Biol Chem.
275:31145–31154. 2000.PubMed/NCBI
|
|
2.
|
Liu J, Yuan Y, Huan J and Shen Z:
Inhibition of breast and brain cancer cell growth by BCCIPα, an
evolutionarily conserved nuclear protein that interacts with BRCA2.
Oncogene. 20:336–345. 2001.PubMed/NCBI
|
|
3.
|
Meng X, Liu J and Shen Z: Genomic
structure of the human BCCIP gene and its expression in cancer.
Gene. 302:139–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Fan J, Wray J, Meng X and Shen Z: BCCIP is
required for the nuclear localization of the p21 protein. Cell
Cycle. 8:3019–3024. 2009.PubMed/NCBI
|
|
5.
|
Lu H, Guo X, Meng X, Liu J, Allen C, Wray
J, Nickoloff JA and Shen Z: The BRCA2-interacting protein BCCIP
functions in RAD51 and BRCA2 focus formation and homologous
recombinational repair. Mol Cell Biol. 25:1949–1957. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Meng X, Liu J and Shen Z: Inhibition of G1
to S cell cycle progression by BCCIPβ. Cell Cycle. 3:343–348.
2004.PubMed/NCBI
|
|
7.
|
Meng X, Lu H and Shen Z: BCCIP functions
through p53 to regulate the expression of p21Waf1/Cip1.
Cell Cycle. 3:1457–1462. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Meng X, Fan J and Shen Z: Roles of BCCIP
in chromosome stability and cytokinesis. Oncogene. 26:6253–6260.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wray J, Liu J, Nickoloff JA and Shen Z:
Distinct RAD51 associations with RAD52 and BCCIP in response to DNA
damage and replication stress. Cancer Res. 68:2699–2707. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lu H, Huang YY, Mehrotra S, Droz-Rosario
R, Liu J, Bhaumik M, White E and Shen Z: Essential roles of BCCIP
in mouse embryonic development and structural stability of
chromosomes. PLoS Genet. 7:e10022912011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. CA Cancer J Clin. 62:10–29. 2012.
|
|
12.
|
Jemal A, Siegel E, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics. CA Cancer J Clin. 57:43–66.
2007.
|
|
13.
|
Sameer AS: Colorectal cancer: molecular
mutations and polymorphisms. Front Oncol. 3:1142013. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Schwab LP, Peacock DL, Majumdar D, Ingels
JF, Jensen LC, Smish KD, Cushing RC and Seagroves TN:
Hypoxia-inducible factor 1α promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast Cancer Res.
14:R62012.
|
|
15.
|
McDonald PC, Winum JY, Supuran CT and
Dedhar S: Recent developments in targeting carbonate anhydrase IX
for cancer therapeutics. Oncotarget. 3:84–97. 2012.PubMed/NCBI
|
|
16.
|
Law AY and Wong CK: Stanniocalcin-2 is a
HIF-1 target gene that promotes cell proliferation in hypoxia. Exp
Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Choschzick M, Oosterwijk E, Müller V,
Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of
carbonic anhydrase IX (CAIX) is an independent unfavorable
prognostic marker in endometrioid ovarian cancer. Virchows Arch.
459:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Seeber LM, Horrée N, Vooijs MA, Heintz AP,
van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia
inducible factor-1 alpha in gynecological cancer. Crit Rev Oncol
Hematol. 78:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; Chicago, IL: 2010
|
|
20.
|
Tavassoli FA and Devilee P: Patholology
and genetics Tumors of the breast and female genital organs. World
Health Organization Classification of Tumors. IARC Press; Lyon:
2003
|
|
21.
|
Gilks CB, Ionescu DN, Kalloger SE, Köbel
M, Irving J, Clarke B, Santos J, Le N, Morravan V and Swenerton K:
Tumor cell type can be reproducibly diagnosed and is of independent
prognostic significance in patients with maximally debulked ovarian
carcinoma. Hum Pathol. 39:1239–1251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Mostofi FK: Histological typing of kidney
tumors. World Health Organization International Classification of
Tumors. Springer-Verlag; New York, NY: 1998
|
|
23.
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Merlo A: Genes and pathways driving
glioblastomas in humans and murine disease models. Neurosurg Rev.
26:145–158. 2003.PubMed/NCBI
|
|
25.
|
Ohgaki H, Dessen P, Jourde B, Horstmann S,
Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM,
Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM
and Kleihues P: Genetic pathways to glioblastoma: a
population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Powell SN and Kachnic LA: Roles of BRCA1
and BRCA2 in homologous recombination, DNA replication fidelity and
the cellular response to ionizing radiation. Oncogene.
22:5784–5791. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Daniels MJ, Wang Y, Lee M and Venkitaraman
AR: Abnormal cytokinesis in cells deficient in the breast cancer
susceptibility BRCA2. Science. 306:876–879. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Rudkin TM and Foulkes WD: BRCA2: breaks,
mistakes and failed separations. Trends Mol Med. 11:145–148. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lu H, Yue J, Meng X, Nickoloff JA and Shen
Z: BCCIP regulates homologous recombination by distinct domains and
suppresses spontaneous DNA damage. Necleic Acids Res. 35:7160–7170.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Liu J, Lu H, Ohgaki H, Merlo A and Shen Z:
Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas.
BMC Cancer. 9:2682009. View Article : Google Scholar : PubMed/NCBI
|
